Comparative Pharmacology
Head-to-head clinical analysis: ASTRAMORPH PF versus DURAGESIC 75.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASTRAMORPH PF versus DURAGESIC 75.
ASTRAMORPH PF vs DURAGESIC-75
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mu-opioid receptor agonist; produces analgesia, sedation, and euphoria by mimicking endogenous endorphins.
Fentanyl is a potent opioid agonist primarily at the mu-opioid receptor, exerting its analgesic effects by mimicking endogenous endorphins and enkephalins to activate G-protein-coupled inwardly rectifying potassium channels, leading to hyperpolarization and reduced neuronal excitability in pain pathways.
Intravenous: 8-10 mg over 2-5 minutes; may be repeated every 8-12 hours as needed. Oral (immediate release): 10-20 mg every 4-6 hours as needed. Oral (extended release): 10-40 mg every 12 hours.
Adults: Apply one 75 mcg/hr transdermal patch every 72 hours. Start with lower dose in opioid-naive patients.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours; prolonged in renal impairment (up to 12 hours in anuria) and elderly
22-25 hours after removal of patch; increased in elderly, hepatic/renal impairment
Renal: 70-80% unchanged; Biliary/Fecal: 10-20% as metabolites
Renal (75% as metabolites, <10% unchanged), fecal (25%)
Category C
Category C
Opioid Analgesic
Opioid Analgesic